Tracking thinking changes after CAR-T cell therapy
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This study tests a quick iPad tool to check for thinking or memory problems that can happen after CAR-T cell therapy. It may help find early signs of brain-related side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received CAR-T cell therapy
- Can see well enough to use an iPad (20/100 vision or better)
- You are 18 years or older
- Able to use an iPad (no severe hand or arm problems)
- You can agree to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses blood tests and brain imaging to better understand and predict nerve-system side effects that can happen after CAR T-cell treatment. It may help doctors spot people at higher risk sooner and guide safer care.
This study is for people getting CAR-T cell therapy, a type of cancer treatment that uses your own immune cells. Researchers want to understand a rare side effect called neurotoxicity by looking at tiny particles in your blood called extracellular vesicles.
This study tests if checking your pupil size with a small light device can predict brain-related side effects from CAR-T cell therapy. It is for patients with certain lymphomas receiving axi-cel CAR-T treatment in the hospital.
This trial looks at how CAR-T treatment affects the brain and thinking skills. It aims to better understand and help with side effects like confusion or memory problems.
This study looks at how a special type of immunotherapy called CAR-T therapy might affect your thinking skills, memory, and ability to focus. By checking on patients early and often, the team hopes to find simple ways to detect and manage these side effects sooner.
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
Hear when a new Neurotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.